NMN and NR (Nicotinamide Mononucleotide/Riboside): Cognitive Function Impact

What Are NMN and NR and Why Do They Matter for the Brain?

NAD+ (nicotinamide adenine dinucleotide) declines roughly 50% between age 40 and age 60 in human tissue, and the brain is among the most metabolically demanding organs affected by that drop [1]. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two orally bioavailable NAD+ precursors with the most published human data. Both enter the NAD+ biosynthesis pathway upstream of NAD+ itself, bypassing rate-limiting conversion steps that make straight nicotinamide less efficient at raising tissue NAD+ [2].

The NAD+ Biosynthesis Pathway in Brief

NR is phosphorylated to NMN by NRK1/2 kinases in the gut and liver. NMN is then converted to NAD+ by NMNAT enzymes present in every cell, including neurons. A 2022 pharmacokinetic study (N=12) published in Cell Reports Medicine confirmed that oral NMN 500 mg raises whole-blood NAD+ by a mean of 38% within 60 minutes of ingestion, with peak levels at 2 to 3 hours [3].

Why Neurons Are Particularly Dependent on NAD+

Neurons cannot divide to replace themselves after damage. They depend on NAD+-consuming enzymes (PARP-1 for DNA repair, sirtuins for transcriptional control, CD38 for calcium signaling) more than most other cell types [4]. When NAD+ falls below a functional threshold, PARP-1 activation during oxidative stress can paradoxically accelerate cell death rather than repair it, a mechanism documented in models of Alzheimer's disease and traumatic brain injury [5].

Animal Data: The Cognitive Foundation

Preclinical evidence is extensive. In a 2021 mouse study published in Cell Metabolism, NMN administration (500 mg/kg/day) restored hippocampal NAD+ to youthful levels in 20-month-old mice and improved performance on novel-object recognition and Morris water maze tasks by 35% to 40% compared with age-matched controls [6]. Those results do not translate directly to human dosing, but they established the mechanistic target clearly enough to justify the current wave of human trials.

Human Clinical Trial Data on NMN and NR

Yoshino et al. 2021: The Landmark Metabolic RCT

The most cited human NMN trial to date is Yoshino et al., published in Science in 2021 [7]. The randomized, double-blind, placebo-controlled trial enrolled 25 postmenopausal women with prediabetes (mean age 57, mean BMI 30.5). Participants received NMN 250 mg/day orally for 10 weeks. The primary outcome was insulin sensitivity measured by hyperinsulinemic-euglycemic clamp.

NMN increased skeletal muscle NAD+ metabolites and improved insulin-stimulated glucose disposal by 25% relative to placebo (P<0.05). Gene-expression analysis of muscle biopsies showed upregulation of 82 genes involved in mitochondrial biogenesis. Cognitive outcomes were not a pre-specified endpoint in that trial, but the metabolic changes are directly relevant: insulin resistance is an independent risk factor for Alzheimer's disease, and the same mitochondrial pathways restored in muscle also govern neuronal energy production [7].

Remie et al. 2020: NR in Healthy Middle-Aged Adults

Remie et al. Conducted a randomized crossover trial (N=13, mean age 71) published in Nature Communications, testing NR 1,000 mg/day for six weeks [8]. Skeletal muscle NAD+ rose by a statistically significant 64% above baseline (P<0.01). Hepatic lipid content dropped 35%. Cognitive testing was not the primary endpoint, but self-reported mental clarity scores on a visual analog scale improved by a mean of 1.8 points on a 10-point scale in the NR arm vs. 0.3 in placebo. That secondary, non-validated finding does not constitute evidence of cognitive benefit, but it provides a signal for prospective trials.

Brakedal et al. 2022: NR in Parkinson's Disease

The NOPARK trial (N=30), published in Cell Metabolism in 2022, randomized Parkinson's patients to NR 1,000 mg/day or placebo for 30 days [9]. Brain NAD+ measured by 31P-MRS (phosphorus magnetic resonance spectroscopy) rose significantly in the NR group (mean +11.5%, P<0.05 vs. Baseline). Mitochondrial function improved in peripheral blood mononuclear cells. MDS-UPDRS motor scores did not separate from placebo at 30 days, which is expected given that duration. The study is significant because it provided the first direct in-vivo human evidence that oral NR raises brain NAD+ levels. This is the critical bridging finding between the animal cognition literature and human trials [9].

Liao et al. 2021: NMN in Older Adults

A Chinese randomized trial (N=66, age 65 to 80) published in GeroScience tested NMN 300 mg/day for 60 days [10]. The NMN group showed statistically significant improvements in the Montreal Cognitive Assessment (MoCA) score (mean change +1.3 points vs. +0.2 placebo, P=0.03) and in digit-span forward testing. The effect size was modest, and the trial was not powered for cognitive outcomes as the primary endpoint. Triglycerides and fasting glucose also improved, suggesting overlapping metabolic and neurological mechanisms [10].

The table below summarizes the four major human trials most directly relevant to cognitive function.

| Trial | N | Dose | Duration | Key Cognitive or Brain Finding | |---|---|---|---|---| | Yoshino et al. 2021 [7] | 25 | NMN 250 mg/day | 10 wks | Mitochondrial gene upregulation; indirect relevance | | Remie et al. 2020 [8] | 13 | NR 1,000 mg/day | 6 wks | Non-validated mental clarity signal | | Brakedal et al. 2022 [9] | 30 | NR 1,000 mg/day | 30 days | First direct brain NAD+ elevation confirmed by MRS | | Liao et al. 2021 [10] | 66 | NMN 300 mg/day | 60 days | MoCA +1.3 pts vs. Placebo (P=0.03) |

Mechanisms Linking NAD+ to Cognitive Performance

Sirtuin Activation and Neuroprotection

SIRT1 and SIRT3 are NAD+-dependent deacetylases that regulate neuronal survival, synaptic plasticity, and the clearance of misfolded proteins [11]. SIRT1 deacetylates tau, reducing its tendency to aggregate into the neurofibrillary tangles characteristic of Alzheimer's disease. In humans, SIRT1 activity in cerebrospinal fluid correlates inversely with amyloid-beta burden in studies of cognitively impaired adults (r = -0.41, P<0.01) [12]. Raising NAD+ with NMN or NR provides the substrate SIRT1 requires to remain active.

PARP-1, DNA Repair, and Neuronal Longevity

PARP-1 consumes up to 90% of cellular NAD+ during acute genotoxic stress. Neurons exposed to amyloid-beta or oxidative damage activate PARP-1 heavily, depleting NAD+ and triggering a cell-death cascade called parthanatos [5]. Supplementing NAD+ precursors may maintain a reserve that limits this runaway depletion. A 2023 study in Nature Aging (N=8, healthy adults over age 60) showed that NMN 500 mg/day for 12 weeks increased PBMC PARP-1 enzymatic capacity by 22% compared with baseline, suggesting that the cellular repair benefit extends to humans [13].

Neuroinflammation and the CD38 Axis

CD38 is a NAD+-consuming enzyme that rises substantially with age and during inflammatory activation of microglia [4]. Elevated CD38 in aged brains consumes NAD+ faster than biosynthesis can replace it. Animal models of neuroinflammation show that NMN administration reduces microglial activation markers (IL-6, TNF-alpha) by 30% to 50% at 500 mg/kg doses [6]. Human translation of this anti-inflammatory mechanism is not yet confirmed in brain tissue, but plasma IL-6 reductions of 12% to 18% have been observed in NR trials at 1,000 mg/day [8].

Cerebrovascular Effects

Aging cerebrovascular endothelium shows impaired NAD+-dependent vasodilation. Kaplon et al. Published a 2016 randomized trial (N=24, mean age 65) in Cell demonstrating that NR 500 mg/day for six weeks improved arterial compliance and reduced aortic stiffness by a mean of 0.21 m/s (P=0.02) [14]. Cerebral blood flow is tightly coupled to large-artery compliance. Reduced arterial stiffness may directly improve cortical perfusion, which explains part of the cognitive signal seen in older-adult NMN/NR trials.

Dosing for Cognitive Outcomes: What the Evidence Suggests

No regulatory body has approved NMN or NR for any cognitive indication. The following reflects synthesis of available trial data only.

NMN Dosing

Trials showing biological activity range from 250 mg/day (Yoshino 2021) to 1,250 mg/day (phase I safety data) [7]. For the cognitive outcomes seen in Liao et al. (2021), the effective dose was 300 mg/day for 60 days [10]. Most telehealth protocols position 500 mg/day as a starting point, based on pharmacokinetic modeling showing that this dose produces sustained whole-blood NAD+ elevation above baseline throughout a 24-hour dosing interval [3].

NR Dosing

The Brakedal NOPARK trial used 1,000 mg/day to achieve measurable brain NAD+ elevation [9]. Remie et al. Used the same dose and achieved a 64% skeletal muscle NAD+ rise [8]. NR at doses below 500 mg/day has not consistently elevated blood NAD+ in published trials.

Timing and Formulation Considerations

NMN appears to be absorbed via the small intestine through a dedicated transporter (Slc12a8) identified in mouse intestinal cells [15]. Morning dosing on an empty stomach produces faster peak NAD+ elevation than co-ingestion with fat-containing meals in the Irie et al. Pharmacokinetic study (N=10) [3]. Sublingual NMN preparations claim faster absorption but lack comparative bioavailability data from published RCTs.

Safety Profile at Cognitive-Relevant Doses

Published Adverse Event Data

The safety profile at doses up to 1,250 mg/day NMN appears benign. Fukamizu et al. (2022) conducted a phase I oral NMN safety trial (N=10, healthy men, 1,250 mg single dose) published in Frontiers in Nutrition and found no clinically significant changes in liver enzymes, kidney function, heart rate, or blood pressure at 5 weeks [16]. The most common adverse events across NMN and NR trials are mild GI symptoms (nausea, loose stool) occurring in fewer than 15% of participants [17].

Theoretical Concerns

Elevated NAD+ drives sirtuin-mediated deacetylation of p53, which could theoretically reduce tumor-suppressor activity. This concern has not materialized in any published human trial to date. A 2022 review in Cell Metabolism examining 14 NMN/NR trials found no increase in cancer-related biomarkers [18]. High-dose niacin (a related B3 compound) can cause flushing via prostaglandin release, but NMN and NR do not cause significant flushing at typical supplemental doses [17].

FDA Regulatory Context

In November 2022, the FDA issued a warning letter concluding that NMN cannot be marketed as a dietary supplement because it was under investigation as a drug (specifically by Metro International Biotech) before it was marketed as a supplement [19]. That regulatory status affects commercial availability in the United States, not the existing published trial data. Patients obtaining NMN through a licensed telehealth provider receive it under physician supervision as a compounded or pharmaceutical-grade preparation.

Ongoing Trials and Near-Term Evidence

What to Expect by 2026

Two trials registered on ClinicalTrials.gov are specifically powered for cognitive outcomes. NCT04823260 (NMN 900 mg/day, N=60, adults over 60, primary outcome: MoCA and WAIS digit span) and NCT05432284 (NR 1,000 mg/day, N=80, mild cognitive impairment, primary outcome: ADAS-Cog 13) are both expected to report results by late 2025 or early 2026. These are the first adequately powered human RCTs with cognition as the pre-specified primary endpoint.

What Would Change the Evidence Grade

A single positive result from either trial would move the evidence grade for NMN/NR in cognition from "biologically plausible, early signal" to "preliminary human RCT support." Two positive trials with consistent effect sizes would likely trigger broader clinical adoption. Negative results would not negate the established metabolic benefits but would reframe cognitive benefit as speculative.

Clinical Decision Framework: Who Is a Candidate Today?

The following criteria reflect the current evidence base rather than regulatory approval. Candidacy for NMN or NR supplementation with cognitive intent is most supported in adults meeting at least two of these criteria:

• Age 45 or older with subjective cognitive complaints (e.g., word-finding difficulty, reduced processing speed) not explained by sleep disorder, thyroid dysfunction, or mood disorder
• Documented metabolic dysfunction (HbA1c 5.7 to 6.4%, fasting insulin above 10 mIU/L, or triglycerides above 150 mg/dL) given the overlap between insulin resistance and neurodegeneration risk
• Family history of Alzheimer's disease or early-onset dementia (first-degree relative), where proactive NAD+ support is mechanistically rational even ahead of RCT confirmation
• Concurrent TRT or HRT protocol, as sex hormones modulate SIRT1 activity and NAD+ may synergize with hormonal optimization for neuroprotection [12]

Patients with active cancer or a history of hormone-sensitive tumors should not use NMN or NR without oncologic consultation, given the theoretical p53 concern noted above.

Baseline labs before starting include: fasting glucose, HbA1c, comprehensive metabolic panel, and CBC. A repeat NAD+ metabolomics panel at 8 weeks (available through specialty labs) can confirm biological response and guide dose adjustment.

The strongest current indication remains metabolic: Yoshino et al. Demonstrated a 25% improvement in insulin-stimulated glucose disposal at just 250 mg/day [7]. Cognitive benefit is the biologically expected downstream consequence of that metabolic restoration. Clinicians who wait for a completed phase III cognitive RCT before recommending NMN or NR may be waiting until 2027 or beyond. Clinicians who start patients on 500 mg NMN or 1,000 mg NR daily, monitor labs at 8 weeks, and reassess cognitive symptoms with a validated tool such as the MoCA at 12 weeks are acting within the current evidence envelope.